--Two-Year Follow-Up Results Confirm Significant Efficacy and No
Serious Adverse Effects in Patients Using StemSpine® Procedure
for Treating Chronic Lower Back Pain --
PHOENIX, March 23, 2022 /PRNewswire/ -- Creative
Medical Technology Holdings, Inc. ("Creative Medical Technology" or
the "Company") (NASDAQ: CELZ), a leading commercial stage
biotechnology company focused on a regenerative approach to
immunotherapy, urology, neurology, and orthopedics, today announced
positive two-year follow-up data for the Company's StemSpine® pilot
study, showing significant efficacy of the StemSpine® procedure for
treating chronic lower back pain without any serious adverse
effects reported.
StemSpine® is a patented procedure that utilizes a
patient's own bone marrow aspirate for the treatment of chronic
lower back pain.
There were no safety related concerns at up to two years and the
StemSpine® procedure resulted in an efficacy rate of 87% in the
treated patients. The Company plans to submit a manuscript for
publication in a peer reviewed journal and present the data at
future orthopedic/sports medicine conferences.
"The positive two-year data from our StemSpine® pilot study are
very encouraging, and we are excited to engage with practitioners
on commercialization," said Timothy
Warbington, President and CEO of the Company. "To our
knowledge, this pilot is the first demonstration of the clinical
efficacy of injecting bone marrow aspirate in areas surrounding the
disc, thereby repairing, remodeling and improving the blood supply
around the disc and lower back area. We believe StemSpine®
represents an attractive non-surgical option for many of the
millions of Americans who suffer from non-surgical chronic lower
back pain."
Sahil Nock, Chief
Commercialization Officer of the Company, added, "Given our timely
receipt of this significant and favorable data, I look forward to
accelerating our StemSpine® program by introduction to the
physician community at the American Academy of Orthopaedic Surgeons
annual conference taking place in Chicago this week, March 22-26. Building out strong advisory boards
with notable KOLs has been a pillar of my career and I am excited
to leverage my experience to accelerate our efforts to translate
the StemSpine® procedure."
The Company plans to hold a series of 1:1 meetings with
physicians throughout the conference. Please contact
Sahil Nock utilizing information
found at the end of this press release if you would like to
connect. We may also be contacted through our website at
www.StemSpine.com.
About Creative Medical Technology Holdings
Creative
Medical Technology Holdings, Inc. is a commercial stage
biotechnology company specializing in stem cell technology in the
fields of immunotherapy, urology, neurology, and orthopedics. For
further information about the Company, please visit
www.creativemedicaltechnology.com.
Forward Looking Statements
This news release may
contain forward-looking statements including but not limited to
comments regarding the timing and content of upcoming clinical
trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions
and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in
such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and
Exchange Commission and available on the Commission's website at
www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/creative-medical-technology-announces-positive-top-line-results-for-stemspine-pilot-study-301508295.html
SOURCE Creative Medical Technology Holdings, Inc.